Business
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium\nCanada NewsWire\nMONTREAL, Nov. 12, 2020\n\n\n\nAmikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco™ preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 /CNW Telbec/ -  Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company,  announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of  Ethacrynate Sodium have commenced in the U.S. market.  \n\n \n \n \n \n \n \n\n \n\"The approval of Amikacin adds to our portfolio of hospital specialty products, an important and growing part of our revenue stream\", said Steve Saviuk, President and CEO. \"We are also pleased with the commercial uptake of Ethacrynate Sodium, our first product launched in the U.S. market.\"\n\"Valeo experienced strong revenue growth in the fourth quarter (ended October 31st) which was aided by the recent launches of Yondelis and Ametop, they combined to contribute 20% of the quarter's revenues,\"added Saviuk. \"We look for revenue growth to accelerate in the coming quarters through both organic growth and additional product launches\".\n\"We have also been receiving heightened commercial and scientific interest in Hesperco™, a flavonoid capsule formula that supports the body's immune system\", continued Saviuk. \"Hesperco™ is available online through our www.Hesperco.com website and will soon be available through retailers and Amazon in Canada. We are proceeding with registration of Hesperco&#...